HeartSciences (HSCS) Stock Price, News & Analysis

Company Overview

HeartSciences, Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms.

Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.

Key Stats

• Today's Range: $3.45 to $3.62
• 50-Day Range: $3.01 to $3.77
• 52-Week Range: $2.52 to $6.47
• Volume: 25,814 shs
• Average Volume: 62,503 shs
• Market Capitalization: $9.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.50
• Consensus Rating: Hold

HeartSciences Stock Analysis - MarketRank™

HeartSciences scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

HeartSciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

HeartSciences has a consensus price target of $10.50, representing about 199.1% upside from its current price of $3.51.

Amount of Analyst Coverage

HeartSciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for HeartSciences are expected to grow in the coming year, from ($10.01) to ($8.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HeartSciences is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HeartSciences is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HeartSciences has a P/B Ratio of 19.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.55% of the float of HeartSciences has been sold short.

Short Interest Ratio / Days to Cover

HeartSciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HeartSciences has recently increased by 28.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HeartSciences does not currently pay a dividend.

Dividend Growth

HeartSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.55% of the float of HeartSciences has been sold short.

Short Interest Ratio / Days to Cover

HeartSciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HeartSciences has recently increased by 28.17%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.95

News Sentiment

HeartSciences has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for HeartSciences this week, compared to 0 articles on an average week.

Search Interest

5 people have searched for HSCS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added HeartSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, HeartSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,633.00 in company stock.

Percentage Held by Insiders

Only 1.80% of the stock of HeartSciences is held by insiders.

Percentage Held by Institutions

Only 17.24% of the stock of HeartSciences is held by institutions.

HSCS Stock Analysis - Frequently Asked Questions

How have HSCS shares performed this year?

HeartSciences' stock was trading at $3.82 at the beginning of the year. Since then, HSCS stock has decreased by 8.1% and is now trading at $3.51.

How were HeartSciences' earnings last quarter?

HeartSciences Inc. (NASDAQ:HSCS) announced its earnings results on Thursday, September, 11th. The company reported ($1.58) EPS for the quarter, topping analysts' consensus estimates of ($2.41) by $0.83.

When did HeartSciences' stock split?

HeartSciences shares reverse split on Friday, May 17th 2024.The 1-100 reverse split was announced on Friday, May 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did HeartSciences IPO?

HeartSciences (HSCS) raised $9 million in an initial public offering (IPO) on Wednesday, June 15th 2022. The company issued 1,800,000 shares at $4.50-$5.50 per share. The Benchmark Company acted as the underwriter for the IPO.

How do I buy shares of HeartSciences?

Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HeartSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HeartSciences investors own include Meta Platforms (META), Cardio Diagnostics (CDIO), Invesco QQQ (QQQ), RH (RH), Exxon Mobil (XOM), Amarin (AMRN) and American Express (AXP).

Company Calendar

• Last Earnings: 9/11/2025
• Today: 10/15/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:HSCS
• CIK: 1468492
• Web: heartsciences.com
• Phone: 682-237-7781
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HeartSciences: $10.50
• High Price Target: $12.00
• Low Price Target: $9.00
• Potential Upside/Downside: +199.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.77 million
• Net Margins: N/A
• Pretax Margin: -146,133.33%
• Return on Equity: -383.38%
• Return on Assets: -145.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.47
• Quick Ratio: 1.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 19.50

Miscellaneous

• Outstanding Shares: 2,650,000
• Free Float: 2,600,000
• Market Cap: $9.30 million
• Optionable: Not Optionable
• Beta: 2.57